Da eksponeringen af Keppra til intravenøs brug har været begrænset og da orale og intravenøse formuleringer er bioækvivalente, vil information vedrørende sikkerheden af Keppra givet intravenøst bero på Keppra givet oralt.
Since there was limited exposure for Keppra intravenous use and since oral and intravenous formulations are bioequivalent, the safety information of Keppra intravenous will rely on Keppra oral use.